Please assess the completion status of the following clinical trial:

Trial Title: Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent.~* HER2+ status defined as IHC 3+ staining or in situ hybridization positive~* Patients with resistance to trastuzumab~* Prior taxane therapy~* Patients with an ECOG performance status of 0 - 2~* Patients with measurable disease as per RECIST criteria~* Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study;~* Patients must meet laboratory criteria defined in the study within 21 days prior to randomization~Exclusion Criteria:~* Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer~* More than three prior chemotherapy lines for advanced disease.~* Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed \>8 weeks prior to randomization~* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus~* Peripheral neuropathy ≥ grade 2 at randomization~* Active cardiac disease~* History of cardiac dysfunction~* Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer~* Known hypersensitivity to any study medication~* Breastfeeding or pregnant

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus + vinorelbine + trastuzumab (Type: EXPERIMENTAL): Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
- placebo + vinorelbine + trastuzumab (Type: PLACEBO_COMPARATOR): Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only

Based on this trial design, predict the completion outcome and termination type (if applicable).